Human microbiome is a collection of micro-organisms that resides in skin, mammary glands, placenta, uterus, seminal fluid, ovarian follicles, lung, saliva, oral mucosa, conjunctiva, and gas intestinal tracts. Human microbiome’s main objective is to recognize and distinguish between microorganism which is associated with both healthy and diseased humans. Some pathogenic micro-organisms can harm human hosts through the metabolites they produce in the body, such as tri-methylamine. Microbiome is responsible for development and metabolic process such as brain function, food digestion and vitamin synthesis the human body. Human microbiome have a significant impact in diagnosing and treating human diseases. Global human microbiome market is anticipated to grow with a CAGR of 21% during forecast period 2016-2023. Growing incidences of life style diseases is the key factor for the market growth. Focus on R&D activities, participation with leading health institutions, such as International Agency for Research on Cancer (IARC) are also encouraging innovation in the market.
Microorganisms in the human body are used for the treatment of disease Lactobacillus. Probiotics are products contain live bacteria that are good for the health such as Lactobacillus. It helps to ease the symptoms of irritable bowel syndrome (IBS) in some people on consumption of dairy products. It is estimated that almost 500 to 1,000 species of bacteria are present in the human body such as Firmicutes and Bacteroidetes, Proteobacteria, Verrumicrobia, Actinobacteria, Fusobacteria. A number of bacteria such as Actinomycin viscous and A. naeslundii, present in the mouth, they are part of a sticky substance called plaque. The same bacteria secrete acids that dissolve tooth enamel, causing tooth decay. Other factors to the growth of human microbiome market are automated and advanced Instruments work on accuracy. Such as Colon Polyp and Colon Cancer Test which will introduced in the market by metabolising 2018. Moreover, the rising cases of the cardiac diseases and other disease such as obesity are expected to contribute to the growth of human Microbiome market. Excessive use of antibiotics which sometimes results in side effects on consumption is also another factor contributing to the growth of human Microbiome market. Market is expected to proliferate with in five to seven years. Lack of technical professional, lack of awareness regarding the beneficial use, lack of efforts towards research and development may be the restricting factor towards the growth of human Microbiome market.
In the present scenario, The prebiotics are acting as a key factor which are enhancing the demand which include the rising awareness considering the various crucial properties of the product such as weight loss, better digestion and lowering the risk of heart disease which results in heart attack.
Genome, Merck & Co., Vedanta Biosciences, symberix, symbiotic biotherapies, rebiotix, metabogin, Actoginics, Miomics, metabiomics,osel, ritter pharmaceuticals, avidbiotics,E.I. du Pont de Nemours and Company are some of the major players in human microbiome market. The market potential in these countries is large considering the market structure in these countries. Global human microbiome market is expected to have significant impact in diagnosing and treating diseases. Bifidobacterium is beneficial in treatment of infant diarrhoea. Microbiome market is emerging market with huge number of opportunities such as more focus on the use of probiotics and prebiotics. Vedanta Biosciences is one of the pioneer companies in human Microbiome segment field with capability to manufacture Andres archon live bacterial consortia. The European patent is an important addition to the global intellectual property portfolio of Vedanta biosciences. This is intellectual property addition put Vedanta in comfortable position to commercialize drug based on bacterial consortia. Vedanta biosciences have built a platform for the development, and manufacturing of drugs based on live commensal microbes. The Company engaged in the first large deal in the field of microbiome in a landmark licensing agreement with Johnson & Johnson with milestone payments of up to $339 million. The Company recently expanded a new headquarters and research and development facility in Cambridge USA.
Source: OBRC Analysis
The report is widely categorized on the basis of market segments includes products, disease and application.
Products is further sub segmented into:
- PROBIOTICS
- FOODS
- PREBIOTICS
- MEDICAL FOODS
- DIAGNOSTIC DEVICES
- DRUGS
- OTHER PROBIOTIC SUPLLEMENTS
The application segment is further sub segmented into:
- THERAPEUTICS
- DIAGNOSTICS
The disease segment is further sub segmented into:
- ACUTE DIARRHOEA
- OBESITY
- DIABETES
- AUTOIMMUNE DISORDER
- CANCER
- MENTAL DISORDER
The revenue for the above application segments are specific to the human microbiome market. However, the total revenue of these application in general has been excluded from the scope of the report. Also, the total market revenue has been calculated by summing up product segment.
Geographically, the global Human Microbiome market has been segmented on the basis of four major regions, which include:
- North America (U.S. & Canada)
- Asia Pacific (China, India, Japan, RoAPAC)
- Europe (UK, France, Germany, RoE)
- Rest of World
On the basis of Geography the market is divided into North America, Europe, and Asia–pacific, rest of the world. Europe region are the major contributor in human microbiome market with immense potential and opportunities and innovations in drug based on bacterial consortia. Additionally, changes in lifestyle of people led to increase in a number of diseases, rising aging population mainly in European countries, gradually demands of efficient and safe medication with no side effects.
The major market players of the global human microbiome market are:
- ACTOGENIX
- AVIDBIOTICS
- METABIOMICS
- METABOGEN
- OSEL
- IMMUNO MICROBIOME COMPANY
Why to buy the report:
This report will:
- Provide you the business strategies adopted by market player such as Flagship Ventures announced the merger of its portfolio companies Evelo Biosciences and Epiva Biosciences to create the leading immune-microbiome company.
- Provide in detail the different segments such as by products and end-users which are affecting the global Proteomics market.
- Provide you the patent analysis of the Proteomics market.
- Identify and understand the strength, opportunities, challenges and threat of the Human Microbiome market.
- Provide revenues of major players of the market such as Symbiotic and Enterome bioscience.
- Provide you various the regulatory policies which are affecting the global Human Microbiome market.
How we are different from others:
At Occam’s we provide an extensive portfolio which is comprehensive market analysis along with the market size, market share, and market segmentations. Our report on global human microbiome market offers the longest chain of market segmentation covering major market segmentation based on products and end users. The report tracks the major market trends in the global human microbiome market such as increasing incidences of life style diseases and so on. For each market segments covered in global human microbiome report, we provide opportunity matrix, and DROC analysis, that enable the clear growth assessment across each market segment. The report discusses competitive landscape of the human microbiome industry, with giving extensive strategy analysis of more than 15 companies. Moreover, the report discusses various models such as 360 degree analysis, See-Saw analysis, and Porter five force model and so on. For the high level analysis in the report we provide a comparative analysis of historic and current year data.
Key findings of the human microbiome market are as follows:
- The factor of early detection and diagnosis of diseases in human microbiome is fuelling growth in global human microbiome market.
- North America is anticipated to generate the largest revenue share in 2016.
- Enhancing government support.
- Mergers & acquisitions is the key strategy adopted by the various market players of global Human Microbiome market.
- In 2016, Flagship Ventures announced the merger of its portfolio companies Evelo Biosciences and Epiva Biosciences to create the leading immune-microbiome company, developing therapeutics for cancer, autoimmune and inflammatory diseases.
